Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-response study of gevokizumab in type 2 diabetes with diabetic kidney disease
2013-003610-41Phase 2Terminated
- Sponsor
- Servier
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gevokizumab in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Servier. Primary endpoint: Measured glomerular filtration rate. Started Dec 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003610-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003610-41.